AbbVie submits applications for treatment of chronic disease

Treatment of chronic disease

AbbVie has announced the submission of applications seeking the approval of upadacitinib, (RINVOQ®, 15 mg once daily) for the treatment of adults with active non-radiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation who have responded inadequately to nonsteroidal anti-inflammatory drugs (NSAIDs).

The submissions to the FDA and EMA are supported by the Phase III SELECT-AXIS 2 (Study 2) clinical trial.

read more